Quick orientationEvidence update: 6 October 2026
What is TB-500?
TB-500 naming is frequently blurred with thymosin beta-4 and fragments. Evidence for one chemical identity cannot automatically be assigned to another.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Thymosin beta-4 has extensive preclinical repair biology; evidence for products sold as TB-500 is much thinner.
What the mechanism suggests
Research-market name commonly associated with a fragment/derivative concept related to thymosin beta-4; exact identity is often unclear.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Research-market name commonly associated with a fragment/derivative concept related to thymosin beta-4; exact identity is often unclear.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Evidence gap
For this exact compound/use, the page does not pretend that animal, cell, ingredient-level or neighbouring-compound evidence is a human clinical result.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Why there is no big human-results graph here
Evidence-gap noteFor this exact compound and the popular use described on this page, we did not identify a robust controlled human outcome trial suitable for a numerical “before versus after” graph. Rather than manufacture certainty, the page keeps mechanistic/preclinical evidence in its proper lane.
An empty evidence slot is useful information. It tells you where the marketing story is running ahead of the clinical one.
What it doesn't prove: Absence of a highlighted trial is not proof that no study exists; it means no sufficiently robust, directly relevant study was selected for a headline quantitative claim in this edition.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Synthetic full-length Tβ4 | 42, 140, 420 or 1,260 mg IV; single dose then | 14 days | Ascending parallel cohorts | Human randomized safety |
| healthy volunteers | same regimen daily ×14 days | study — full-length Tβ4 | ||
| Recombinant human Tβ4 Phase I | 0.05–25 µg/kg IV single-dose cohorts | Single dose | Ascending cohorts | Human Phase I — full-length recombinant Tβ4 |
| Recombinant multiple-dose | 0.5, 2 or 5 µg/kg IV once daily | 10 days | Fixed cohorts | Human Phase I — full-length recombinant Tβ4 |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Older TB-500 loading | ~2–6 mg/week SC, divided into 2 | 4–6 weeks | Higher loading then lower | Community |
| convention | administrations | maintenance | ||
| Prime Life protocol | 1 mg twice weekly week 1 →1–2.5 mg twice weekly weeks 2–8 | 8 weeks; 4–8 week washout claimed | Increase by ~0.25–0.5 mg per dose as needed | Clinic/community |
| Alternative | 5 mg once weekly weeks 1–4 →2.5 mg | 10 weeks + break | 5→2.5 mg | Clinic/community |
| loading/maintenance | weekly weeks 5–10 →2 weeks off |
TB-500 sold online is generally described as a fragment/analogue and is not interchangeable with full-length thymosin-β4 used in human IV studies. PP must not cite full-length Tβ4 trials as proof that mg-level SC TB-500 works.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Compound identity and product quality are major uncertainties.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
An empty evidence slot is useful information. It tells you where the marketing story is running ahead of the clinical one.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.